Copolymer, medical composition, covering medical device, and method for producing same

By using multipolymers containing carboxybetaine, sulfobetaine, (meth)acrylic acid and acrylamide derivatives, the problems of complicated surface treatment operations and insufficient biocompatibility and durability of medical equipment are solved, and the problem of incompatibility and durability of medical equipment is achieved. Excellent biocompatibility maintenance under frictional stimulation.

CN118922459APending Publication Date: 2024-11-08TORAY INDUSTRIES INC

Patent Information

Application Number
CN202380029363.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-01-30
Filing Date
2023-04-07
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing surface treatment methods for medical equipment are complicated to operate and the durability of biocompatibility is insufficient, making it difficult to maintain excellent biocompatibility under frictional stimulation.

Method used

Non-crosslinked linear or branched random copolymers are prepared by polymerization process for covering. Medical equipment surface, providing excellent biocompatibility.

Benefits of technology

It achieves the simplicity of the surface of medical equipment to give excellent biocompatibility, and maintains its biocompatibility under frictional stimulation, avoids complicated operations and improves the service life of the equipment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118922459A_ABST
    Figure CN118922459A_ABST
Patent Text Reader

Abstract

The purpose of the present invention is to provide: a copolymer which is capable of imparting excellent biocompatibility to the surface of a medical device by a simple process and which is capable of maintaining the biocompatibility over a long period of time; a method for producing the copolymer; and the like. The present invention provides a copolymer containing (A), (B), and (C) as monomer components. (A) A compound having a carboxyl betaine group and / or a sulphobetaine group; (B) (meth) acrylic acid; and (C) an acrylamide derivative.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a copolymer, a medical composition and a covered medical device, and methods for producing the same. Background Art

[0002] Medical devices such as contact lenses and stents that come into direct contact with living organisms need to have biocompatibility. In order to ensure safety and improve the wearing feel, the surface of contact lenses needs to have biocompatibility such as water wettability, lubricity and antifouling properties. Stents are implanted medical devices that can be left in the body, and complications caused by the adhesion of thrombi, platelets, mucus, etc. are considered a serious issue. In particular, for respiratory stents, there is a huge clinical demand for long-term use stents that inhibit mucus adhesion and improve biocompatibility. As a representative method for imparting excellent biocompatibility to the surface of medical devices, surface treatment of medical devices is known.

[0003] As surface treatment methods for medical devices, known methods include: a method of stacking and coating polymers having different properties (Patent Document 1); a method of coating a polymer containing an amphoteric electrolyte compound (Patent Document 2); or a method of coating a random copolymer of N-(meth)acryloyloxyethyl-N,N-dimethylammonium-α-N-methylcarboxybetaine and butyl methacrylate (Patent Document 3), etc.

[0004] Prior art literature

[0005] Patent Literature

[0006] Patent Document 1: International Publication No. 2013 / 024801

[0007] Patent Document 2: Japanese Patent Application No. 2014-520191

[0008] Patent Document 3: Japanese Patent No. 4961133 Summary of the invention

[0009] Problems to be solved by the invention

[0010] However, conventional surface treatment methods for medical devices often involve complicated operations, and furthermore, the durability of biocompatibility obtained by surface treatment is insufficient at present.

[0011] Therefore, an object of the present invention is to provide a copolymer which can impart excellent biocompatibility to the surface of a medical device by a simple process and can maintain its biocompatibility even when exposed to friction stimulation, and a method for producing the same.

[0012] Means for solving problems

[0013] In order to achieve the above-mentioned problem, the present invention provides the following copolymer, which contains the following (A), (B) and (C) as monomer components:

[0014] (A) a compound having a carboxybetaine group and / or a sulfobetaine group;

[0015] (B) (meth)acrylic acid;

[0016] (C) Acrylamide derivatives.

[0017] Effects of the Invention

[0018] According to the present invention, it is possible to provide a copolymer that can impart excellent biocompatibility to the surface of a medical device without complicated operations and can maintain its biocompatibility even when exposed to friction stimulation. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Figure 1 This is a graph showing the amount of mucin adhesion on silicone hydrogel lenses.

[0020] Figure 2 This is a graph showing the amount of mucin adhesion on a hydrogel lens.

[0021] Figure 3 This is a graph showing the amount of lysozyme attached to a silicone hydrogel lens.

[0022] Figure 4 This is a graph showing the amount of lysozyme attached to a hydrogel lens.

[0023] Figure 5 This is a graph showing the amount of mucin adhesion on silicone hydrogel lenses.

[0024] Figure 6 This is a graph showing the amount of mucin adhesion on a hydrogel lens.

[0025] Figure 7 This is a graph showing the amount of lysozyme attached to a silicone hydrogel lens.

[0026] Figure 8 This is a graph showing the amount of lysozyme attached to a hydrogel lens.

[0027] Fig. 9 This is a graph showing the amount of mucin adhesion on airway stents. DETAILED DESCRIPTION

[0028] The copolymer of the present invention is a multi-component copolymer (hereinafter referred to as "copolymer T") comprising (A) a compound having a carboxybetaine group and / or a sulfobetaine group, (B) (meth)acrylic acid and (C) an acrylamide derivative as monomer components.

[0029] The copolymer of the present invention is non-crosslinked and can be linear or branched. From the viewpoint of ease of manufacture, it is preferably linear. The copolymer of the present invention can be any of a random copolymer, an alternating copolymer, a block copolymer or a graft copolymer. From the viewpoint of ease of manufacture, it is preferably a random copolymer.

[0030] The "monomer component" that is the raw material of the copolymer of the present invention refers to a low molecular weight compound that can be polymerized and / or cross-linked using a photopolymerization initiator and / or a thermal polymerization initiator. In addition, the copolymer containing the above-mentioned (A), (B) and (C) as monomer components means that the copolymer contains a structure derived from the above-mentioned monomer components (A), (B) and (C).

[0031] Regarding the (A) “compound having a carboxybetaine group and / or a sulfobetaine group” (hereinafter referred to as “monomer component (A)”) as one of the monomer components, for example, 2-[[2-(methacryloyloxy)ethyl]dimethylammonio]acetic acid, 3-[[2-(methacryloyloxy)ethyl]dimethylammonio]propionic acid (hereinafter referred to as “CBMA”), 3-[(3-acrylamidopropyl)dimethylammonio]propionic acid (hereinafter referred to as “CBAA”), 3-[[2-(methacryloyloxy)ethyl]dimethylammonio]propane-1-sulfonic acid (hereinafter referred to as SBMA), 4-[[2-(methacryloyloxy)ethyl]dimethylammonio]butane-1-sulfonic acid, 3-[[2-(acryloyloxy)ethyl]dimethylammonio]propane-1-sulfonic acid (SPDA), bis[2-(methacryloyloxy)ethyl](methyl)ammonio]propane-1-sulfonic acid, 3-[(3-methacrylamidepropyl)dimethylammonio]propane-1-sulfonic acid, 4-[(3-methacrylamidepropyl)dimethylammonio]butane-1-sulfonic acid or 3-[(3-acrylamidepropyl)dimethylammonio]propane-1-sulfonic acid. From the viewpoint of non-adsorption properties of proteins, CBMA or SBMA is preferred.

[0032] (B) "(meth)acrylic acid" (hereinafter referred to as "monomer component (B)") as one of the monomer components refers to methacrylic acid and / or acrylic acid (hereinafter referred to as "AA"), and acrylic acid is preferred from the viewpoint of polymerization stability.

[0033] As for the (C) "acrylamide derivative" (hereinafter referred to as "monomer component (C)") as one of the monomer components, for example, acrylamide, N-isopropylacrylamide, N,N-dimethylacrylamide (hereinafter referred to as "DMAA"), N,N-diethylacrylamide, N-methyl-N-ethylacrylamide or N,N-di(hydroxyethyl)acrylamide can be mentioned. From the viewpoint of polymerization stability, DMAA is preferred.

[0034] Regarding the proportions of the monomer component (A), the monomer component (B) and the monomer component (C) in the copolymer of the present invention, the monomer component (A) is preferably 1 to 40 mol%, the monomer component (B) is preferably 1 to 35 mol%, and the monomer component (C) is preferably 25 to 98 mol%.

[0035] The proportion of the monomer component (A) in the copolymer of the present invention is more preferably 1 to 30 mol %, and even more preferably 5 to 25 mol %.

[0036] The proportion of the monomer component (B) in the copolymer of the present invention is more preferably 1 to 25 mol %, and even more preferably 5 to 15 mol %.

[0037] The proportion of the monomer component (C) in the copolymer of the present invention is more preferably 45 to 98 mol %, and even more preferably 60 to 90 mol %.

[0038] The method for producing a copolymer of the present invention comprises a polymerization step of polymerizing monomers containing (A) a compound having a carboxybetaine group and / or a sulfobetaine group, (B) (meth)acrylic acid, and (C) an acrylamide derivative to obtain a copolymer.

[0039] In the polymerization step, a polymerization initiator such as a thermal polymerization initiator or a photopolymerization initiator may be used to polymerize and / or crosslink the monomer components.

[0040] Examples of the thermal polymerization initiator include peroxides and azo compounds. The thermal polymerization initiator may be selected from those having optimal decomposition characteristics at a desired reaction temperature, and generally, azo compounds or peroxides having a 10-hour half-life temperature of 40 to 120°C are preferred.

[0041] More specifically, examples thereof include 2,2'-azobisisobutyronitrile (AIBN), 2,2'-azobis(2-methylbutyronitrile), 2,2'-azobis(2,4-dimethylvaleronitrile), 1,1'-azobis(cyclohexane-1-carbonitrile), 2,2'-azobis[2-(2-imidazolin-2-yl)propane], 2,2'-azobis(2-methylpropionamidine) dihydrochloride (hereinafter referred to as "V-50"), 2, 2'-Azobis[N-(2-carboxyethyl)-2-methylpropionamidine], 2,2'-azobis[2-methyl-N-(2-hydroxyethyl)propionamide], 2,2'-azobis(N-butyl-2-methylpropionamide), 2,2'-azobis(2-methylpropionic acid) dimethyl ester, 4,4'-azobis(4-cyanovaleric acid), tert-butyl hydroperoxide, isopropylbenzene hydroperoxide, di-tert-butyl peroxide or benzoyl peroxide.

[0042] Examples of the photopolymerization initiator include aromatic α-hydroxyketones, alkoxyoxybenzoin, acetophenone, carbonyl compounds such as acylphosphine oxide or bisacylphosphine oxide, tertiary amines + diketones, peroxides, azo compounds, sulfur compounds, halogen compounds, or metal salts.

[0043] More specifically, for example, 1-hydroxycyclohexyl phenyl ketone, 2-hydroxy-2-methyl-1-phenyl-propane-1-one, bis(2,6-dimethoxybenzoyl)-2,4,4-trimethylpentylphosphine oxide (DMBAPO), bis(2,4,6-trimethylbenzoyl)phenylphosphine oxide ("Irgacure" (registered trademark) 819), 2,4,6-trimethylbenzyldiphenylphosphine oxide and 2,4,6-trimethylbenzoyldiphenylphosphine oxide, benzoin methyl ether or a combination of camphorquinone and ethyl 4-(N,N-dimethylamino)benzoate.

[0044] These polymerization initiators may be used alone or in combination. In order to appropriately promote polymerization and crosslinking of the monomer components and obtain a copolymer of a desired molecular weight, the proportion of the polymerization initiator in the polymerization mixture is preferably 5% by mass or less.

[0045] Here, the "polymerization mixture" refers to a mixture obtained by dissolving each monomer component for obtaining a copolymer, a polymerization initiator, and a chain transfer agent optionally added as needed in a solvent.

[0046] Examples of the solvent used to obtain the polymerization mixture include alcohol solvents such as water, methanol, ethanol, propanol, 2-propanol, butanol, 2-butanol, tert-butanol, tert-amyl alcohol, 3,7-dimethyl-3-octanol, ethylene glycol, diethylene glycol, triethylene glycol, tetraethylene glycol, and polyethylene glycol; aromatic hydrocarbon solvents such as benzene, toluene, and xylene; aliphatic hydrocarbon solvents such as hexane, heptane, octane, decane, petroleum ether, kerosene, volatile oil (ligroin), and paraffin; Agent; alicyclic hydrocarbon solvents such as cyclopentane, cyclohexane or ethylcyclohexane; ketone solvents such as acetone, methyl ethyl ketone or methyl isobutyl ketone; ester solvents such as ethyl acetate, butyl acetate, amyl acetate, ethyl lactate, methyl benzoate or ethylene glycol diacetate; or ether solvents such as diethyl ether, tert-butyl methyl ether, tetrahydrofuran, dioxane, ethylene glycol dimethyl ether, diethylene glycol dimethyl ether, triethylene glycol dimethyl ether, tetraethylene glycol dimethyl ether or polyethylene glycol dimethyl ether. These solvents can be used alone or in combination. From the viewpoint of not being easy to hinder free radical polymerization, the solvent is preferably water, methanol, tert-butyl alcohol, tert-amyl alcohol, 3,7-dimethyl-3-octanol or tetrahydrofuran, or a mixed solvent thereof, and more preferably water.

[0047] In order to appropriately suppress runaway due to polymerization heat and obtain a copolymer having a desired molecular weight, the total proportion of the monomer components in the polymerization mixture is preferably 10 to 80% by mass, more preferably 15 to 65% by mass.

[0048] In the polymerization step, the polymerization mixture is heated to cause a polymerization reaction, thereby obtaining a desired copolymer.

[0049] The reaction temperature in the polymerization step may be selected based on the decomposition temperature of the polymerization initiator, the boiling points of the solvent and the monomers, the reaction time, etc. In order to obtain the desired copolymer in good yield, it is preferably 20°C to 180°C, more preferably 50°C to 150°C, and even more preferably 60 to 120°C.

[0050] The reaction time in the polymerization step may be selected according to the type and concentration of the polymerization initiator and monomer used, the reaction temperature, etc., and is preferably 1 to 48 hours, more preferably 2 to 24 hours, and even more preferably 3 to 12 hours in order to obtain the desired copolymer in good yield.

[0051] In order to obtain a moderate solution viscosity (handling properties) and suitable lubricity, the weight average molecular weight (hereinafter referred to as "Mw") of the copolymer of the present invention is preferably 1,000 to 5,000,000, more preferably 5,000 to 3,000,000, and even more preferably 10,000 to 1,000,000.

[0052] In the covered medical device of the present invention, at least a part of the surface of the medical device is covered with the copolymer of the present invention.

[0053] The material of the medical device may be any of a water-containing base material such as hydrogel (including silicone hydrogel), an acrylic resin such as polymethyl methacrylate, a silicone base material having a siloxane bond, a metal such as aluminum, or a non-water-containing base material such as glass.

[0054] Examples of the medical device include ophthalmic lenses, skin covering materials, wound covering materials, skin protective materials, skin drug carriers, infusion tubes, gas delivery tubes, drainage tubes, blood circuits, covering tubes, catheters, stents, sheaths, biosensor chips, artificial heart-lungs, and endoscope covering materials. Among these, medical devices selected from ophthalmic lenses and stents are preferred because they have a high requirement for the effects of the present invention.

[0055] Examples of ophthalmic lenses include contact lenses such as soft contact lenses, hard contact lenses, and hybrid contact lenses; scleral lenses, intraocular lenses, artificial corneas, corneal inlays, corneal onlays, and spectacle lenses. Among them, contact lenses are preferred.

[0056] As a stent, a stent for respiratory organs is preferred. The respiratory organ in the present invention is a general term for organs related to breathing, and examples thereof include the respiratory tract, oral cavity, nasal cavity, larynx, trachea, bronchi, bronchioles, lungs, etc. The stent described in the embodiment of the present invention is a stent for respiratory organs, preferably a stent for the respiratory tract, trachea, bronchi or lungs.

[0057] The medical composition of the present invention comprises the copolymer of the present invention and a solvent. The medical composition of the present invention is used to cover at least a portion of the surface of a medical device with the copolymer of the present invention to obtain the covered medical device of the present invention.

[0058] The method for producing the medical composition of the present invention comprises a preparation step of mixing the copolymer of the present invention and a solvent to obtain the medical composition.

[0059] Examples of the solvent used in the preparation step include the same solvents as those used to obtain the above-mentioned "polymerization mixture".

[0060] In order to make the thickness of the coating layer appropriate and to improve the viscosity (handling properties) of the solution, the proportion of the copolymer of the present invention in the medical composition of the present invention is preferably 0.0001 to 30.0000 mass %, more preferably 0.0010 to 20.0000 mass %, and even more preferably 0.0050 to 15.0000 mass %.

[0061] By bringing the medical composition of the present invention into physical contact with the surface of a medical device, the surface of the medical device can be covered with the copolymer of the present invention. That is, the method for producing a covered medical device comprises the following covering step: bringing the medical composition of the present invention into contact with the surface of a medical device to obtain a covered medical device. For example, if the medical device is an ophthalmic lens, the surface of the ophthalmic lens can be covered with the copolymer of the present invention by enclosing the medical composition of the present invention and the ophthalmic lens in a container so that they are in contact, and then performing a heating treatment (covering step).

[0062] Examples of the heating method include high-pressure steam method, electromagnetic wave irradiation such as visible light, infrared or microwave, electric heating method, electromagnetic induction heating method, dry heat method or flame method. From the viewpoint of improving water wettability and lubricity and shortening the manufacturing process, high-pressure steam method using an autoclave is preferred.

[0063] In order to obtain a covered medical device surface that maintains the strength of the medical device itself and exhibits good water wettability and lubricity, the heating temperature in the above-mentioned heating operation is preferably 60 to 200°C, more preferably 80 to 180°C, further preferably 100 to 170°C, and particularly preferably 110 to 150°C.

[0064] In order to obtain a covered medical device surface that maintains the strength of the medical device itself and exhibits good water wettability and lubricity, the heating time in the above heating operation is preferably 5 to 600 minutes, more preferably 10 to 400 minutes, and even more preferably 15 to 300 minutes.

[0065] The initial pH of the medical composition of the present invention is preferably 2.0 to 6.0 from the viewpoint of preventing the composition from becoming turbid and obtaining a medical device having good transparency, surface wettability and lubricity, and the initial pH is more preferably 2.2 to 5.0, further preferably 2.4 to 4.5, and particularly preferably 2.5 to 4.0.

[0066] The pH of the medical composition of the present invention can be adjusted by, for example, adding an acidic substance. Examples of the acidic substance include acetic acid, citric acid, formic acid, ascorbic acid, trifluoromethanesulfonic acid, methanesulfonic acid, nitric acid, sulfuric acid, phosphoric acid, and hydrochloric acid. Citric acid, ascorbic acid, or sulfuric acid, which are low in volatility and highly safe for living organisms, are preferred. In addition, a buffer may be added to the medical composition of the present invention in order to facilitate fine adjustment of the pH.

[0067] Examples of the buffer include boric acid, sodium borate and other borates; citric acid, potassium citrate and other citrates; bicarbonates such as sodium bicarbonate; phosphates such as Na2HPO4, NaH2PO4 or KH2PO4; TRIS (tris(hydroxymethyl)aminomethane), 2-bis(2-hydroxyethyl)amino-2-(hydroxymethyl)-1,3-propanediol, bisaminopolyol, triethanolamine, ACES (N-(2-acetamido)-2-aminoethanesulfonic acid), BES (N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid), HEPES (4-(2 -hydroxyethyl)-1-piperazineethanesulfonic acid), MES (2-(N-morpholino)ethanesulfonic acid), MOPS (3-[N-morpholino]-propanesulfonic acid), PIPES (piperazine-N,N'-bis(2-ethanesulfonic acid) or TES (N-[tris(hydroxymethyl)methyl]-2-aminoethanesulfonic acid), or salts thereof. In order to achieve the desired pH, the proportion of the buffer in the medical composition of the present invention is preferably 0.001 to 2.000 mass %, more preferably 0.010 to 1.000 mass %, and even more preferably 0.050 to 0.300 mass %.

[0068] It should be noted that the pH of the medical composition of the present invention may change during the coating process such as the heating operation. For example, in order to optimize the physical properties of the obtained coated medical device, the pH of the medical composition immediately after the heating operation (before pH adjustment) is preferably 2.0 to 6.5, more preferably 2.2 to 5.9, further preferably 2.3 to 5.5, and particularly preferably 2.4 to 5.0.

[0069] The covered medical device obtained by the above-mentioned covering step may be further subjected to other treatments. Here, examples of other treatments include: a treatment in which the same covering step as above is repeated, a treatment in which a solvent or buffer solution not containing the copolymer of the present invention is brought into contact with the surface of the covered medical device and the same heating operation is performed, radiation irradiation, LbL treatment (Layer by Layer treatment) in which polymer materials having opposite charges are alternately applied layer by layer, crosslinking treatment using metal ions, or chemical crosslinking treatment.

[0070] The pH of the buffer solution used in the heat treatment is preferably a physiologically acceptable pH of 6.3 to 7.8, more preferably 6.5 to 7.6 or higher, and even more preferably 6.8 to 7.4.

[0071] Example

[0072] Hereinafter, the present invention will be specifically described by way of Examples etc., but the present invention is not limited thereto. First, the analysis method and the evaluation method in the Examples etc. will be described.

[0073] The composition of the phosphate buffer used was as follows: KCl: 0.2 g / L, KH2PO4: 0.2 g / L, NaCl: 8.0 g / L, Na2HPO4: 1.2 g / L, EDTA: 0.5 g / L.

[0074] (1) Determination of polymer Mw and number average molecular weight (Mn)

[0075] The molecular weight of the polymer was measured using a Prominence GPC system (manufactured by Shimadzu Corporation). The configuration of the apparatus is as follows.

[0076] Pump: LC-20AD, automatic sampler: SIL-20AHT, column oven: CTO-20A, detector: RID-10A, column: GMPWXL (manufactured by Tosoh Corporation; inner diameter 7.8 mm × 30 cm, particle size 13 μm). As the elution solvent, water / methanol = 1 / 1 (added with 0.1N lithium nitrate) was used, and the measurement was carried out under the conditions of a flow rate of 0.5 mL / min and a measurement time of 30 minutes. It should be noted that the sample concentration was set to 0.1% by mass and the sample injection volume was set to 20 μL. The standard curve was prepared using PEG / PEO standard samples (manufactured by Agilent; 0.1-1500k).

[0077] (2) Water wettability (liquid film retention time)

[0078] After cleaning the covered medical device or medical device (hereinafter referred to as "test sample") with phosphate buffer at room temperature, immerse it in phosphate buffer at room temperature and let it stand for more than 24 hours. The test sample (hereinafter referred to as "test sample S") is lifted from the phosphate buffer and held in the air in such a way that its length direction becomes the direction of gravity. In the case where the test sample is in the shape of a lens, it is held in the air in such a way that the diameter direction of the circle formed by the edge of the lens becomes the direction of gravity. Visually observe the time from the moment when the test sample S begins to be held in the air to the time when a part of the liquid film covering the surface of the test sample S is broken, and determine the average value of N=3 according to the following criteria. It should be noted that "part of the liquid film is broken" means that the liquid film on the surface of the test sample S cannot maintain its shape, and a part of the surface of the test sample S is no longer covered by the liquid film.

[0079] A: The liquid film on the surface is maintained for more than 20 seconds.

[0080] B: The surface liquid film breaks in 15 seconds or more and less than 20 seconds.

[0081] C: The surface liquid film breaks in 5 seconds or more and less than 15 seconds.

[0082] D: The surface liquid film breaks in more than 1 second and less than 5 seconds.

[0083] E: The liquid film on the surface breaks instantly (less than 1 second).

[0084] (3) Lubricity

[0085] The sensitivity evaluation was conducted when the test sample S lifted out of the phosphate buffer solution was rubbed five times with human fingers, with N=1, and the evaluation was made according to the following criteria.

[0086] A: Very excellent lubricity (a finger slides on the surface of the test sample S as if flowing, and no resistance is felt at all).

[0087] B: Slightly superior lubricity (intermediate between A and C).

[0088] C: Moderate lubricity (a finger slides on the surface of the test sample S and almost no resistance is felt).

[0089] D: Almost no lubricity (intermediate between C and E).

[0090] E: No lubricity (fingers cannot easily slide on the surface of the sample S and significant resistance is felt).

[0091] (4) Moisture content

[0092] After wiping the surface of the test sample S lifted from the phosphate buffer with a wiping cloth "キムワイプ" (registered trademark) (manufactured by Nippon Paper Corporation), the mass (Ww) of the substrate is measured. Thereafter, the test sample S is dried at 60°C for 2 hours using a vacuum dryer, and its mass (Wd) is measured. Based on their mass, the moisture content of the test sample is calculated using the following formula (1). When the obtained value is less than 1%, it is judged to be below the detection limit and is expressed as "less than 1%". The average value of N=3 is taken as the moisture content.

[0093] The moisture content of the sample under test (%) = 100 × (Ww-Wd) / Ww...Formula (1).

[0094] (5) Friction coefficient

[0095] The friction coefficient of the surface of the test sample S in a state wetted with the phosphate buffer solution was measured under the following conditions, and the average value of N=5 was taken as the friction coefficient.

[0096] Equipment: Friction Tester KES-SE (manufactured by KATOTECH Co., Ltd.)

[0097] Friction sensitivity: H

[0098] Measuring speed: 2×1mm / sec

[0099] Friction load: 44g.

[0100] (6) Lipid adhesion

[0101] Put 0.03g of methyl palmitate, 10g of pure water and the sample to be tested into a 20cc spiral tube. Oscillate the spiral tube at 37°C and 165rpm for 3 hours. After oscillation, use 40°C tap water and household liquid detergent "Mamaremon" (registered trademark) (manufactured by Lion Corporation) to scrub the sample to be tested in the spiral tube. Put the cleaned sample to be tested into a spiral tube filled with phosphate buffer and keep it in a refrigerator at 4°C for 1 hour. Afterwards, visually observe the sample to be tested. If there is a turbid part, it is judged that methyl palmitate is attached. Observe the area of ​​the part with methyl palmitate attached relative to the entire surface of the sample.

[0102] (7) Mucin adhesion

[0103] When the sample to be tested is a contact lens, a test piece with a width (minimum part) of 5 mm and a length of 14 mm was cut out using a punching die (hereinafter referred to as "sample P"). When the sample to be tested is a stent, a test piece with a diameter of 4 mm was cut out using a punching die (hereinafter referred to as "sample K"). As mucin, Mucin, Bovine Submaxillary Gland (manufactured by Millipore; catalog number: 499643) was used to prepare a mucin aqueous solution with a concentration of 0.1% by mass, and sample P or sample K was immersed at 37°C for 22 hours. Thereafter, the amount of mucin attached to sample P or sample K was quantified by BCA (bicinchoninic acid) protein analysis, and the average value of N=3 was taken as the amount of mucin attachment.

[0104] (8) Lysozyme attachment amount

[0105] As lysozyme, egg white-derived lysozyme (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.; catalog number: 127-06724) was used to prepare a 0.1 mass % lysozyme aqueous solution, and the sample P was immersed in it at 37° C. for 22 hours. Thereafter, the amount of lysozyme attached to the sample P was quantified by the BCA protein analysis method, and the average value of N=3 was taken as the amount of lysozyme attached.

[0106] [Example 1]

[0107] 2.29 g (10 mmol) of CBMA (manufactured by Tokyo Chemical Industry Co., Ltd.), 0.72 g (10 mmol) of AA (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.), 7.93 g (80 mmol) of DMAA (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.), 6.8 mg (0.025 mmol) of V-50 (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.) as a polymerization initiator, and 98.49 g of purified water (manufactured by Furukawa Pharmaceutical Co., Ltd.) were added to a 500 mL four-necked flask, and a digital thermometer, a three-way stopcock, and a stopper with a stirring blade were installed. The four-necked flask was evacuated to a pressure of 10 mmHg under ultrasonic irradiation for 5 times, and then nitrogen gas was circulated to remove dissolved oxygen in the mixed solution. Then, the mixture was reacted for 4 hours under stirring at 90° C. on an oil bath, and then the four-necked flask was lifted out of the oil bath and air-cooled to obtain 9.44 g of copolymer T110. The properties of the obtained copolymer T1 are shown in Table 1.

[0108] [Example 2]

[0109] The same operation as in Example 1 was carried out except that 2.79 g (10 mmol) of SBMA (produced by Tokyo Chemical Industry) was used instead of CBMA to obtain 114.45 g of copolymer T2. The properties of the obtained copolymer T2 are shown in Table 1.

[0110] [Comparative Example 1]

[0111] The same operation as in Example 1 was carried out except that 2.95 g (10 mmol) of 2-(methacryloyloxy)ethyl 2-(trimethylammonio)ethyl phosphate (hereinafter referred to as "MPC"; manufactured by Tokyo Chemical Industry Co., Ltd.) was used instead of CBMA to obtain a copolymer T. C1 The properties of the obtained copolymer TC1 are shown in Table 1.

[0112] [Comparative Example 2]

[0113] The same operation as in Example 1 was carried out except that N-vinylpyrrolidone (hereinafter referred to as "NVP"; manufactured by Tokyo Chemical Industry, 1.11 g, 10 mmol) was used instead of CBMA to obtain 97.63 g of copolymer TC2. The properties of the obtained copolymer TC2 are shown in Table 1.

[0114] [Table 1]

[0115] surface

[0116]

[0117] [Example 3]

[0118] As medical device A, a commercially available silicone hydrogel lens "Acuvue Oasys" (registered trademark; manufactured by Johnson & Johnson) with polyvinyl pyrrolidone and silicone as main components was used. Copolymer T1 was added to a phosphate buffer solution in a concentration of 0.3% by mass, and the pH was adjusted to 3.0 using citric acid. 3 mL of the prepared solution was transferred to a glass vial, immersed in medical device A, and heated in an autoclave at 121°C for 30 minutes. After the heated medical device was washed with phosphate buffer for 30 seconds, it was put into a new phosphate buffer solution, and further heated in an autoclave at 121°C for 30 minutes to obtain a covered medical device.

[0119] [Example 4]

[0120] The same operation as in Example 3 was carried out except that the copolymer T2 was used instead of the copolymer T1, thereby obtaining a covered medical device.

[0121] [Example 5]

[0122] As the medical device M, a commercially available hydrogel lens "Medalist" (registered trademark; manufactured by Baush & Lomb) containing N-vinyl pyrrolidone and 2-hydroxyethyl methacrylate (2-HEMA) as main components was used. Except that the medical device M was used instead of the medical device A, the same operation as in Example 3 was performed to obtain a covered medical device.

[0123] [Example 6]

[0124] The same operation as in Example 5 was carried out except that the copolymer T2 was used instead of the copolymer T1, thereby obtaining a covered medical device.

[0125] [Comparative Example 3]

[0126] Use copolymer T C1 The same operation as in Example 3 was carried out except that copolymer T1 was replaced with , to obtain a covered medical device.

[0127] [Comparative Example 4]

[0128] Use copolymer T C2 The same operation as in Example 3 was carried out except that copolymer T1 was replaced with , to obtain a covered medical device.

[0129] [Comparative Example 5]

[0130] Use copolymer T C1 The same operation as in Example 5 was carried out except that copolymer T1 was replaced with , to obtain a covered medical device.

[0131] [Comparative Example 6]

[0132] Use copolymer T C2 The same operation as in Example 5 was carried out except that copolymer T1 was replaced with , to obtain a covered medical device.

[0133] [Comparative Example 7]

[0134] For medical device A, no covered process was evaluated.

[0135] [Comparative Example 8]

[0136] For medical device M, no covering process was performed for evaluation.

[0137] The evaluation results of various covered medical devices obtained in Examples 3 to 6 and Comparative Examples 3 to 8 are shown in Tables 2 and 3, and Figure 1 to Figure 4 .

[0138] [Table 2]

[0139]

[0140] [Table 3]

[0141]

[0142] [Example 7]

[0143] The same operation as in Example 1 was carried out except that 4.59 g (20 mmol) of CBMA, 0.72 g (10 mmol) of AA, 6.94 g (70 mmol) of DMAA and 90.21 g of purified water were used to obtain 122.46 g of copolymer T3. The properties of the obtained copolymer T3 are shown in Table 4.

[0144] [Example 8]

[0145] The same operation as in Example 1 was carried out except that 6.88 g (30 mmol) of CBMA, 0.72 g (10 mmol) of AA, 5.95 g (60 mmol) of DMAA and 98.49 g of purified water were used to obtain 135.47 g of copolymer T4. The properties of the obtained copolymer T4 are shown in Table 4.

[0146] [Example 9]

[0147] The same operation as in Example 1 was carried out except that 5.59 g (20 mmol) of SBMA, 0.72 g (10 mmol) of AA, 6.94 g (70 mmol) of DMAA and purified water (99.22 g) were used instead of CBMA to obtain 132.47 g of copolymer T5. The properties of the obtained copolymer T5 are shown in Table 4.

[0148] [Example 10]

[0149] The same operation as in Example 1 was carried out except that 8.38 g (30 mmol) of SBMA, 0.72 g (10 mmol) of AA, 5.95 g (60 mmol) of DMAA and purified water (115.44 g) were used instead of CBMA to obtain 150.50 g of copolymer T6. The properties of the obtained copolymer T6 are shown in Table 4.

[0150] [Example 11]

[0151] The same operation as in Example 1 was carried out except that 5.59 g (20 mmol) of SBMA, 1.44 g (20 mmol) of AA, 5.95 g (60 mmol) of DMAA and 96.78 g of purified water were used instead of CBMA to obtain 129.77 g of copolymer T7. The properties of the obtained copolymer T7 are shown in Table 4.

[0152] [Comparative Example 9]

[0153] The same operation as in Example 1 was carried out except that SBMA 5.59 g (20 mmol), AA 2.88 g (40 mmol), DMAA 3.97 g (40 mmol) and purified water (91.91 g) were used instead of CBMA to obtain a copolymer T C3 124.35 g. The obtained copolymer T C3 The properties are shown in Table 4.

[0154] [Comparative Example 10]

[0155] The same operation as in Example 1 was carried out except that 2.16 g (30 mmol) of AA, 6.94 g (70 mmol) of DMAA and 61.91 g of purified water were used to obtain a copolymer T C4 91.02 g. The obtained copolymer T C4 The properties are shown in Table 4.

[0156] [Table 4]

[0157]

[0158] [Examples 12 to 16]

[0159] The same operation as in Example 3 was carried out to obtain a covered medical device, except that the copolymer T shown in Table 5 was used instead of the copolymer T1.

[0160] [Examples 17 to 21]

[0161] The same operation as in Example 5 was carried out to obtain a covered medical device, except that the copolymer T shown in Table 5 was used instead of the copolymer T1.

[0162] [Comparative Examples 11 and 12]

[0163] The same operation as in Example 3 was carried out to obtain a covered medical device, except that the copolymer T shown in Table 5 was used instead of the copolymer T1.

[0164] [Comparative Examples 13 and 14]

[0165] The same operation as in Example 5 was carried out to obtain a covered medical device, except that the copolymer T shown in Table 5 was used instead of the copolymer T1.

[0166] The evaluation results of various covered medical devices obtained in Examples 12 to 21 and Comparative Examples 11 to 14 are shown in Table 5 and Figures 5 to 8 .

[0167] [Table 5]

[0168]

[0169] [Example 22]

[0170] A silicone stent (Dumon stent) was used as the medical device D. The same operation as in Example 12 was carried out except that the medical device D was used instead of the medical device A to obtain a covered medical device.

[0171] [Example 23]

[0172] The same operation as in Example 14 was performed except that medical device D was used instead of medical device A to obtain a covered medical device.

[0173] [Comparative Example 15]

[0174] The same operation as in Comparative Example 12 was performed except that the medical device D was used instead of the medical device A, thereby obtaining a covered medical device.

[0175] [Comparative Example 16]

[0176] Medical device D was evaluated for the amount of mucin adhesion without performing the covering step.

[0177] The evaluation results of the amount of mucin adhesion of various medical device covers obtained in Examples 22 and 23 and Comparative Examples 15 and 16 are shown in FIG. Fig. 9 .

Claims

1. A copolymer comprising the following (A), (B) and (C) as monomer components, (A) a compound having a carboxybetaine group and / or a sulfobetaine group; (B) (meth)acrylic acid; (C) Acrylamide derivatives.

2. The copolymer according to claim 1, wherein The content of the monomer component (A) is 1 to 40 mol%.

3. The copolymer according to claim 1 or 2, wherein The content of the monomer component (B) is 1 to 35 mol%.

4. A medical composition comprising the copolymer according to claim 1 and a solvent.

5. Covered medical devices, where: The copolymer according to claim 1 is coated on the surface of medical equipment.

6. A method for producing a copolymer, comprising the following polymerization steps: A copolymer is obtained by polymerizing monomers containing (A) a compound having a carboxybetaine group and / or a sulfobetaine group, (B) (meth)acrylic acid, and (C) an acrylamide derivative.

7. A method for producing a medical composition, comprising the following preparation steps: The copolymer obtained by the method according to claim 6 is mixed with a solvent to obtain a medical composition.

8. A method for manufacturing a covered medical device, comprising the following covering steps: The medical composition obtained by the method according to claim 7 is brought into contact with the surface of a medical device to obtain a coated medical device.

9. The method for manufacturing a covered medical device according to claim 8, wherein: The medical device is selected from eye lenses, skin covering materials, wound covering materials, skin protective materials, skin drug carriers, infusion tubes, gas delivery tubes, drainage tubes, blood circuits, covering tubes, catheters, stents, sheaths, biosensor chips, artificial hearts and lungs, and endoscope covering materials.

10. The method for manufacturing a covered medical device according to claim 9, wherein: The ophthalmic lens is a contact lens.

Citation Information

Patent Citations

  • Biocompatible, biomimetic, amphoteric electrolyte materials

    JP2014520191A

  • Medical device, and method for producing same

    WO2013024801A1

Cited By

  • A microwave-induced, free-radical-free surface polymer coating preparation method

    CN122750207A